Researchers are zeroing in on understanding what goes awry in the brains of people with Alzheimer’s disease.
Tek Image/Science Photo Library via Getty Images
Despite decades of starts and stops, new treatments and key genetic discoveries are giving researchers great hope for slowing or eventually preventing Alzheimer’s disease.
Donanemab targets amyloid plaques in the brain.
Signal Scientific Visuals/ Shutterstock
Late-stage trial results suggest the drug can slow cognitive decline by 35%.
An illustration of amyloid plaques within the human brain, characteristic features of Alzheimer’s. By 2060, approximately 14 million Americans are expected to have the disease.
Kateryna Kon/Science Photo Library via Getty Images
Although Medicare has agreed to pay for Aduhelm, its coverage comes with restrictions.